Mayo Clinic is active in several areas of research on hyperoxaluria, coordinated through the Mayo Clinic Hyperoxaluria Center and the Rare Kidney Stone Consortium in Rochester, Minnesota. The center maintains an international registry of data on people with hyperoxaluria, compiles statistics on outcomes, and maintains a bank of urine, plasma, blood and liver samples for investigation and collaborative research.
The center offers people the opportunity to participate in clinical trials, testing new diagnosis and treatment approaches.
Ongoing research projects include:
- Genetic mutations in primary hyperoxaluria and correlation with disease outcomes
- New technology for measuring the type of kidney stones on computerized tomography (CT) scans and the ability to fragment them using urologic devices
- Evaluation of new treatments for hyperoxaluria, including use of orally administered oxalate-degrading bacteria (Oxalobacter formigenes), oxalate-degrading enzymes and newer agents that block oxalate synthesis in the liver
- Evaluation of the effect of diet on urine oxalate levels
- Effect of hydroxyproline on urine oxalate levels in people with primary hyperoxaluria
- Quality of life in patients with primary hyperoxaluria and other people who develop kidney stones
See a list of publications by Mayo Clinic doctors on hyperoxaluria on PubMed, a service of the National Library of Medicine.